Alaunos Therapeutics Analyst Ratings
H.C. Wainwright Downgrades Alaunos Therapeutics (TCRT) to a Hold
Alaunos Therapeutics Analyst Ratings
HC Wainwright & Co. Upgrades Alaunos Therapeutics to Buy, Announces $1.5 Price Target
Alaunos Therapeutics (TCRT) Was Upgraded to a Buy Rating at H.C. Wainwright
Wells Fargo Assumes Alaunos Therapeutics at Overweight, Announces Price Target of $3
Wells Fargo Keeps Their Buy Rating on Alaunos Therapeutics (TCRT)
Analysts Offer Insights on Healthcare Companies: Durect (DRRX), Alaunos Therapeutics (TCRT) and Marinus (MRNS)
H.C. Wainwright Sticks to Their Hold Rating for Alaunos Therapeutics (TCRT)
No Data
No Data